Miruvor
Sign up
The short answer

What studies of voice therapy and vocal exercises found

3papers on voice therapy and vocal exercises
1 (few people)person in 1 study testing voice therapy and vocal exercises alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for quality of life.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Voice therapy and vocal exercises might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Voice therapy and vocal exercises · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Daily life and health overall

Quality of life1 study · 1 (few people) person took part in voice therapy and vocal exercises Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · ten sessions twice a week · Each VT session lasted 45 minutes, twice a week (few people)

Quality of life improved.

The evidence is very uncertain about the effect of voice therapy and vocal exercises on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Effectiveness of voice therapy after recovery from COVID-19 infection: A Rare Case Report (2023) preprint

    People in the study
    1 in the study
    Dose
    Each VT session lasted 45 minutes, twice a week
    Outcome
    quality of life related to voice
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Long-term laryngological sequelae and patient-reported outcomes after COVID-19 infection.2023 · no comparison group · 57 in the study
    Summary

    This retrospective chart review examined long-term laryngeal problems after COVID-19 at the Yale COVID clinic between July 2020 and August 2021. Of 57 patients who met inclusion criteria, all had PCR-positive COVID-19 and laryngeal dysfunction. There was no comparison group. Treatments were voice therapy (recommended for 24; 17 underwent), respiratory retraining therapy (recommended for 5; 2 underwent), and procedural interventions such as dilations, steroid injections, excision of stenosis, and cordotomies (10 underwent). Voice therapy follow-up was a mean 260 days (±136 days); procedural patients’ median time to the last follow-up visit at which improvement was reported was 298 days (IQR: 173–408). Outcomes included symptom improvement or resolution, QOL indices (DI, CSI, EAT-10, VHI-10, RSI), and GRBAS ratings. Of 17 voice-therapy patients, 11 (64.7%) reported improvement and 2 (11.8%) resolution; 3 reported persistent symptoms and 1 persistent dysphonia. VHI scores decreased for improvers, and GRBAS scores improved or remained stable. QOL and GRBAS grade scores did not demonstrate other trends. Both respiratory-retraining patients reported improvement in dyspnea. Among 10 procedural patients, all ten (100%) had laryngotracheal stenosis and reported improvement; 7 (70%) needed more than one procedure. Five of these ten had follow-up QOL data showing improvement. Side effects and withdrawals due to harms were not reported. The authors state the study was retrospective, had a moderate sample size, had missing QOL and clinician voice data, and was not powered to detect differences in QOL scores, stroboscopy findings, and interventions between diagnoses.

  2. Isolated Severe Dysphonia as a Presentation of Post-COVID-19 Syndrome.2022 · no comparison group · 158 in the study · 6 started · 6 with outcome data
    Summary

    This study assessed the clinical management of isolated severe dysphonia in post-COVID-19 syndrome at an ENT outpatient clinic and/or post-COVID-19 outpatient clinic in Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz, Poland. Of 158 included patients, six (3.8%) presented with dysphonia as an isolated symptom and were analysed. All six received methylprednisolone p.o. starting at 32 mg per day in descending doses for two weeks, moisturizing inhalations with hyaluronic acid, protective agents with hyaluronic acid, sulphate, and Poloxamer against laryngopharyngeal reflux, and education on vocal hygiene and coping strategies. There was no comparison group. Assessments included VHI, V-RQOL, laryngological examination, LVS, and HSV; examinations were repeated two weeks and one month post-treatment. Reported findings included mean VHI values of 62 before and 34 after treatment, mean V-RQOL values of 57 and 78, mean Jitter of 3.16 pre-treatment and 2.97 post-treatment, and mean Shimmer of 7.16 pre-treatment and 2.77 post-treatment. Post-treatment, no patient had a VHI total score >60 points. Patient 1 had a difference of 36 points in total VHI pre- and post-treatment scores. The paper also reported improvement in vocal fold vibrations, phonovibrogram, morphological condition of the glottis, clinical symptoms, glottis inflammation/hyperemia/dryness, and redness/stiffness of vocal folds. Harms and withdrawals were not reported. No explicit limitations were stated.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime